


IN THE NATURE OF ABRIDGED PROSPECTUS - MEMORANDUM CONTAINING SALIENT FEATURES OF THE RED HERRING PROSPECTUS

	<p>This is an Abridged Prospectus containing salient features of the Red Herring Prospectus of Invicta Diagnostic Limited (the “Company”) dated November 24, 2025 filed with the Registrar of Companies, Mumbai at Maharashtra (the “RHP” or “Red Herring Prospectus”). You are encouraged to read greater details available in the RHP, which is available at https://www.nseindia.com/companies-listing/corporate-filings-offer-documents. Unless otherwise specified all capitalised terms used herein and not specifically defined bear the same meaning as ascribed to then in RHP. This abridged prospectus is not for distribution outside India.</p>
<p>(Please scan this QR code to view the RHP)</p>	<p>THIS ABRIDGED PROSPECTUS CONSISTS OF BID CUM APPLICATION FORM ALONG WITH INSTRUCTIONS AND SIX PAGES OF ABRIDGED PROSPECTUS. PLEASE ENSURE THAT YOU HAVE RECEIVED ALL THE PAGES.</p>
<p>Please ensure that you have read the RHP, this Abridged Prospectus (“Abridged Prospectus”) and the General Information Document for investing in public issues (“GID”) undertaken through the Book Building Process before applying in the Issue (as defined below). The investors are advised to retain a copy of the RHP/Abridged Prospectus for their future reference. You may obtain a physical copy of the Bid cum Application Form and the RHP from the Stock Exchange, Member of the Syndicate, Registrar to the Issue, Registrar and Share Transfer Agents (“RTAs”), Collecting Depository Participants (“CDPs”), Registered Brokers, Bankers to the Issue, Investors’ Associations or Self Certified Syndicate Banks (“SCSBs”). You may also download the RHP from the website of Securities and Exchange Board of India (“SEBI”) at www.sebi.gov.in, the website of National Stock Exchange of India Limited (“NSE”, the “Stock Exchange”) at www.nseindia.com, and the website of the Company at www.pcdiagnostics.in and the website of the Book Running Lead Manager at https://socradamus.in/.</p>	



INVICTA DIAGNOSTIC LIMITED

Corporate Identification Number: U86100MH2023PLC414723; Date of Incorporation: December 01, 2023

Registered Office	Corporate Office	Contact Person	Email and Telephone	Website
1 GF, Plot 217, Ambavat, Bhavan, N.M Joshi Marg, Delisle Road, Mumbai – 400 013, Maharashtra, India	Office No. 1012, 10 th Floor, Hubtown Viva CHS Ltd, Western Express Highway, Mogra Village, Near Shankar Wadi, Jogeshwari East, Mumbai – 400 060, Maharashtra, India	Soniya Niles Mahajan Company Secretary and Compliance Officer	Email: investors@pcdiagnostics.in Telephone: 022 - 4971 0036	www.pcdiagnostics.in

THE PROMOTERS OF OUR COMPANY ARE DR. KETAN JAYANTILAL JAIN, DR. SANKET VINOD JAIN, ROHIT PRAKASH SRIVASTAVA, BADAL KAILASH NAREDI AND JAYESH PRAKASH JAIN

Details of the Issue to the Public							
Type of Offer	Fresh Issue Size	Offer For Sale Size	Total Issue Size	Eligibility and Reservation among QIBs, NIBs & IBs	Share Reservation		
					QIB	NIB	IB
Fresh Issue	Up to 33,08,800 Equity Shares of face value of ₹10/- each aggregating to ₹ [●] Lakhs	Not Applicable	Up to 33,08,800 Equity Shares of face value of ₹10/- aggregating to ₹ [●] Lakhs	The Issue is being made pursuant to Regulation 229 (2) of the Securities and Exchange Board of India (Issue of Capital and Disclosure Requirements) Regulations, 2018, as amended (“SEBI ICDR Regulations”) For further details, see “Other Regulatory and Statutory Disclosures – Eligibility for the Issue” on page 289. For details of share reservation among QIBs, NIBs and IBs, see “Issue Structure” on page 307.	Not more than [●] Equity Shares	Not less than [●] Equity Shares	Not less than [●] Equity Shares

These equity shares are proposed to be listed on SME Platform of National Stock Exchange of India Limited (“NSE Emerge”). For the purpose of the Issue, NSE is the Designated Stock Exchange (“the Designated Stock Exchange”).

DETAILS OF THE SELLING SHAREHOLDERS, OFFER FOR SALE AND WEIGHTED AVERAGE COST OF ACQUISITION			
Name of Selling Shareholder	Type	No of Equity Shares offered	Weighted average cost of acquisition per Equity Share (in ₹)
NA	NA	NA	NA

PRICE BAND, MINIMUM BID LOT & INDICATIVE TIMELINES

Price Band (For details of the Price Band and the basis for the Issue Price, please refer to the price band advertisement and the section titled “Basis for Issue Price” on page 111 of the RHP)	₹80/- per Equity Share to ₹85/- per Equity Share of face value of ₹10/- each
Minimum Bid Lot Size	A minimum of 3200 Equity Shares and in multiples of 1600 Equity Shares thereafter
Bid/ Issue Open On	Monday, 01 December, 2025
Bid/ Issue Closes On*	Wednesday, 03 December, 2025
Finalisation of Basis of Allotment with the Designated Stock Exchange	On or before Thursday, 04 December, 2025
Initiation of Refunds (if any, for Anchor Investors)/ unblocking of funds from ASBA Account	On or before Friday, 05 December, 2025
Credit of Equity Shares to Demat accounts of Allottees	On or before Friday, 05 December, 2025
Commencement of trading of Equity Shares on the Stock Exchange	On or before Monday, 08 December, 2025

* UPI mandate end time and date shall be at 5.00 p.m. on the Bid Closing Date.

Weighted Average Cost of Acquisition of all shares transacted 18 months preceding the date of this Red Herring Prospectus

Period	Number of Equity Shares transacted of face value ₹ 10 each	Weighted average cost of acquisition per Equity Share (in ₹)	Cap Price is ‘x’ times the weighted average cost of acquisition	Range of acquisition price per Equity Share: lowest price-highest price (in ₹)
Trailing Eighteen Months from the date of RHP	8,45,253	71.00	1.20	71.00 - 71.00

*As certified by M/s Kanak Rathod and Co, Chartered Accountants, by way of their certificate dated November 18, 2025.

Disclaimer: The Equity Shares have not been and will not be registered under the U.S. Securities Act of 1933, as amended (“U.S. Securities Act”) and may not be offered or sold within the United States, except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the U.S. Securities Act and applicable state securities law. Accordingly, the Equity Shares are only being offered and sold outside the United States in “offshore transactions” as defined in and in reliance on Regulation S under the U.S. Securities Act and the applicable laws of the jurisdiction where those offers and sales occur. There will be no offering of securities in the United States.

RISKS IN RELATION TO THE FIRST ISSUE

The face value of the Equity Shares is ₹10/- each. The Floor Price, Cap Price and Issue Price determined by our Company in consultation with the Book Running Lead Manager, on the basis of the assessment of market demand for the Equity Shares by way of the Book Building Process, as stated in “Basis for Issue Price” on page 111 of RHP should not be considered to be indicative of the market price of the Equity Shares after the Equity Shares are listed. No assurance can be given regarding an active and / or sustained trading in the Equity Shares nor regarding the price at which the Equity Shares will be traded after listing.

GENERAL RISKS

IN THE NATURE OF ABRIDGED PROSPECTUS - MEMORANDUM CONTAINING SALIENT FEATURES OF THE RED HERRING PROSPECTUS

Investments in equity and equity-related securities involve a degree of risk and investors should not invest any funds in the Issue unless they can afford to take the risk of losing their investment. Investors are advised to read the risk factors carefully before taking an investment decision in the Issue. For taking an investment decision, investors must rely on their own examination of our Company and the Issue, including the risks involved. The Equity Shares in the Issue have not been recommended or approved by the Securities and Exchange Board of India ("SEBI"), nor does SEBI guarantee the accuracy or adequacy of the contents of this Red Herring Prospectus. Specific attention of the investors is invited to "Risk Factors" on page 42 of RHP and on page 8 of this Abridged Prospectus.

PROCEDURE

You may obtain a physical copy of the Bid cum Application Form and the RHP from the Stock Exchange, Syndicate Members, Registrar to the Issue, RTAs, CDPs, Registered Brokers, Underwriters, Bankers to the Issue, Investors' Associations or SCSBs.

If you wish to know about processes and procedures applicable to this Issue, you may request for a copy of the RHP and/or the GiD from the BRLM or download it from the websites of the SEBI at www.sebi.gov.in and NSE at www.nseindia.com and from the website of the BRLM at <https://socradamus.in>.

PRICE INFORMATION OF BRLM

PRICE INFORMATION OF BRLM: SOCRADAMUS CAPITAL PRIVATE LIMITED

Sr. No.	Issue name	Issue size (₹ Crores)	Issue price (₹)	Listing Date	Opening price on Listing Date (₹)	+/- % change in closing price, +/- % change in Closing benchmark] 30 th calendar days from listing	+/- % change in closing price, +/- % change in closing benchmark] 90 th calendar days from listing	+/- % change in closing price, +/- % change in Closing benchmark] 180 th calendar days from listing
SME IPO								
1.	Identical Brains Studios Limited	19.95	54.00	December 26, 2024	95.00	-4.63%, [-2.77%]	-16.94%, [-0.34%]	-21.20%, [-5.14%]
2.	Kaytex Fabrics Limited	69.81	180.00	August 05, 2025	144.00	-37.39% [0.37%]	-50.83% [4.52%]	N.A.

Source: www.nseindia.com

Book Running Lead Manager	Socradamus Capital Private Limited Telephone: 022 – 4961 4235 Email: info@socradamus.in Investors Grievance e-mail: investors@socradamus.in
Name of Syndicate Member	Nikunj Stock Brokers Limited
Name of Market Maker	Nikunj Stock Brokers Limited Telephone: 011 – 4703 0017/9811322534 Email: complianceofficer@nikunjonline.com
Name of Registrar to the Issue	Bigshare Services Private Limited Telephone: 022 – 6263 8200 Email: ipo@bigshareonline.com Investor Grievance e-mail: investor@bigshareonline.com
Name of Statutory Auditor	M/s. Kanak Rathod & Co, Chartered Accountants
Name of Credit Rating Agency and the rating or grading obtained, if any	Not Applicable
Name of Debenture trustee, if any	Not Applicable
Self-Certified Syndicate Banks	The banks registered with SEBI, offering services: (a) in relation to ASBA (other than using the UPI Mechanism), a list of which is available on the website of SEBI at https://www.sebi.gov.in/sebiweb/other/OtherAction.do?doRecognisedFpi=yes&intmId=34 and https://www.sebi.gov.in/sebiweb/other/OtherAction.do?doRecognisedFpi=yes&intmId=35 , as applicable or such other website as may be prescribed by SEBI from time to time; and (b) in relation to ASBA (using the UPI Mechanism), a list of which is available on the website of SEBI at https://www.sebi.gov.in/sebiweb/other/OtherAction.do?doRecognisedFpi=yes&intmId=40 , or such other website as may be prescribed by SEBI from time to time.
SCSBs enabled for UPI Mechanism and eligible mobile application	In accordance with SEBI RTA Master Circular, UPI Bidders Bidding using the UPI Mechanism may apply through the SCSBs and mobile applications whose names appears on the website of the SEBI at https://www.sebi.gov.in/sebiweb/other/OtherAction.do?doRecognisedFpi=yes&intmId=40 and https://www.sebi.gov.in/sebiweb/other/OtherAction.do?doRecognisedFpi=yes&intmId=43 respectively, as updated from time to time.
Syndicate SCSB Branches	In relation to Bids (other than Bids by Anchor Investor) submitted to a member of the Syndicate, the list of branches of the SCSBs at the Specified Locations named by the respective SCSBs to receive deposits of Bid cum Application Forms from the members of the Syndicate is available on the website of the SEBI at https://www.sebi.gov.in/sebiweb/other/OtherAction.do?doRecognisedFpi=yes&intmId=35 and updated from time to time. For more information on such branches collecting Bid cum Application Forms from the Syndicate at Specified Locations, see the website of the SEBI at https://www.sebi.gov.in/sebiweb/other/OtherAction.do?doRecognisedFpi=yes&intmId=35 as updated from time to time.
Registered Brokers	Bidders can submit ASBA Forms in the Issue using the stockbroker network of the stock exchange, i.e., through the Registered Brokers at the Broker Centres. The list of the Registered Brokers eligible to accept ASBA Forms, including details such as postal address, telephone number and e-mail address, is provided on the website of the Stock Exchange at www.nseindia.com , as updated from time to time.
Details regarding website address(es)/ link(s) from which the investor can obtain a list of RTAs, CDPs and stock brokers who can accept applications from investors, as applicable	The list of the RTAs eligible to accept ASBA Forms from Bidders (other than IBs) at the Designated RTA Locations, including details such as address, telephone number and e-mail address, is provided on the website of Stock Exchange at http://www.nseindia.com/products-services/initial-public-offerings-asba-procedures , as updated from time to time. The list of the CDPs eligible to accept ASBA Forms from Bidders (other than IBs) at the Designated CDP Locations, including details such as name and contact details, is provided on the website of NSE at http://www.nseindia.com/products-services/initial-public-offerings-asba-procedures , as updated from time to time. For further details, see "Issue Procedure" at page 311 of the RHP.

PROMOTERS OF OUR COMPANY

Sr. No.	Name	Individual/ Corporate	Experience & Educational Qualification
1.	Dr. Ketan Jayantilal Jain	Individual	Dr. Ketan Jayantilal Jain is the Non-Executive Director on the Board of our Company. He holds a degree in M.B.B.S from Maharashtra University of Health Sciences, Nashik and Diploma in Medical Radiology and Electrolgy from College of Physicians & Surgeons of Mumbai. He has around 16 years of experience as consultant radiologist with various hospitals and diagnostic centres in past and has founded and managed a diagnostic facility, Asian Imaging for more than a decade. He is associated as consultant radiologist with one of our group companies, Primacare Diagnostic LLP and is also a consultant radiologist with our company since 2021. His role includes ensuring quality assurance and regulatory compliance of our diagnostic centres.
2.	Dr. Sanket Vinod Jain	Individual	Dr. Sanket Vinod Jain is the Chairman and Non-Executive Director on the Board of our Company. He holds the Degree of M.B.B.S. from MGM Institute of Health Sciences and a M.D. (Radiodiagnosis) from Bharati Vidyapeeth Deemed University, Pune. He has approximately 6 years of experience as a

IN THE NATURE OF ABRIDGED PROSPECTUS - MEMORANDUM CONTAINING SALIENT FEATURES OF THE RED HERRING PROSPECTUS

			consultant radiologist with our Company since 2021. He looks for performing and interpreting diagnostic imaging procedures, collaborating with physicians to develop treatment plans, and ensuring the accuracy and quality of radiology reports.
3.	Rohit Prakash Srivastava	Individual	Rohit Prakash Srivastava is the Chief Financial Officer of our Company. He holds a Post Graduate Diploma in Management from Symbiosis Centre for Management and Human Resources Development, Pune and a Bachelor of Commerce from University of Mumbai. He has around 20 years of experience across various industries, including Investment Banking, Education, Wealth Management, and Healthcare with expertise in building relationships with High-Net-Worth Individuals, leading teams, and conducting financial structuring. He was previously associated with Axis Bank Limited, Lotus Wealth Advisors Pvt Ltd, IndusInd Bank Limited, The Hongkong and Shanghai Banking Corporation and Canara HSBC OBC Life Insurance Company Limited. He has also co-founded the International School of Business Administration, Pune, where he played a pivotal role in its establishment and growth, showcasing his skills in marketing, finance, and operations management. Prior to joining our company as a full time, he acted as a management advisor to our company since the incorporation of our Erstwhile LLP and then joined as Head – Business Development in February 2023. Currently, as Chief Financial Officer, he looks after the entire operations and finance including expansion, business growth, and profitability of our multi-chain diagnostic centres.
4.	Badal Kailash Naredi	Individual	Badal Kailash Naredi is the Promoter of our Company. He is a Chartered Accountant by qualification and has completed his Masters and Bachelors in Commerce from University of Mumbai. He has around 20 years of experience in Investment Banking and Finance. He is currently associated with Palco Metals Limited as the Chief Financial Officer.
5.	Jayesh Prakash Jain	Individual	Jayesh Prakash Jain is the Promoter of our Company. He has completed his Bachelors in Commerce from University of Mumbai. He has around 18 years of experience in gold jewellery business and was associated with Sanket Jewellers LLP since 2005 as Designated Partner.

For details in respect of our Promoters, please see the section titled “Our Promoters and Promoter Group” beginning on page 227 of the RHP.

OUR BUSINESS OVERVIEW AND STRATEGY

Company Overview: We are a diagnostic chain in Mumbai Metropolitan Region (“MMR”) offering comprehensive radiology and pathology solutions. We offer solution for pathology and radiology testing services such as imaging (including radiology) and pathology/clinical laboratory to customers under the brand name “PC Diagnostics” through our extensive operational network, which consists of 7 diagnostic centres including 1 centralised laboratory across Mumbai Metropolitan Region in the state of Maharashtra.

Product/Service Offering: Our company offerings are diagnostic services across pathology and radiology through a hub-and-spoke network of centres and a centralised laboratory, offering routine and specialized tests supported by advanced imaging modalities and efficient logistics.

Revenue segmentation by product/service offering:

Following is our revenue from operations for periods indicated based on our type of services:

Based on Restated Consolidated Financial Information:

(₹ in lakhs)

Particulars	For the period ended		For the year ended on March 31			
	September 30, 2025		2025		2024	
	Revenue from Operations	% of Total Revenue from Operations	Revenue from Operations	% of Total Revenue from Operations	Revenue from Operations	% of Total Revenue from Operations
Radiology	1,526.10	90.05%	2,719.27	90.36%	1,487.71	93.98%
Pathology	168.63	9.95%	290.25	9.64%	95.34	6.02%
Total	1,694.73	100.00%	3,009.52	100.00%	1,583.05	100.00%

As certified by M/s. Kanak Rathod & Co., Chartered Accountants, by way of their certificate dated November 18, 2025.

Based on Restated Standalone Financial Information:

(₹ in lakhs)

Particulars	For the period ended on		For the year ended on March 31					
	September 30, 2025		2025		2024		2023	
	Revenue from Operations	% of Total Revenue from Operations	Revenue from Operations	% of Total Revenue from Operations	Revenue from Operations	% of Total Revenue from Operations	Revenue from Operations	% of Total Revenue from Operations
Radiology	949.47	89.38%	1,433.34	88.10%	905.06	93.46%	673.18	98.38%
Pathology	112.85	10.62%	193.67	11.90%	63.30	6.54%	11.11	1.62%
Total	1,062.32	100.00%	1,627.02	100.00%	968.36	100.00%	684.29	100.00%

As certified by M/s. Kanak Rathod & Co., Chartered Accountants, by way of their certificate dated November 18, 2025.

For further details, see “Our Business – Our Diagnostic Services” on page 178 of the RHP.

Geographies Served: Our Company caters to domestic markets for our services.

Revenue segmentation by geographies: NA

Key Performance Indicators:

Based on Restated Consolidated Financial Information:

a) **Key financial indicators**

Indicator	For the Period ended	For the year ended	
	April 01, 2025 to September 30, 2025	2025	2024
Revenue from Operations (₹ in Lakhs) ⁽¹⁾	1,694.73	3,009.52	1,583.05
EBITDA (₹ in Lakhs) ⁽²⁾	676.50	919.89	708.68
EBITDA Margin (%) ⁽³⁾	39.92%	30.57%	44.77%
PAT (₹ in Lakhs) ⁽⁴⁾	408.41	492.95	380.54
PAT Margin (%) ⁽⁵⁾	24.10%	16.38%	24.04%
Return on equity (%) ⁽⁶⁾	21.91%	44.28%	55.53%
Return on capital employed (%) ⁽⁷⁾	22.80%	42.00%	56.04%
Investment in Property, Plant and Equipment during the year (₹ in Lakhs) ⁽⁸⁾	737.40	55.58	45.37
Cash Conversion Ratio (times) ⁽⁹⁾	0.74	0.71	0.90

Notes:

(1) Revenue from operations is calculated as revenue from sale of services.

(2) EBITDA is calculated as restated profit before tax, extraordinary and exceptional items plus finance costs, depreciation and amortisation expense minus other income.

(3) EBITDA margin is calculated as a percentage of EBITDA divided by revenue from operations.

(4) PAT represents total profit after tax for the year/period.

(5) PAT margin is calculated as a percentage of PAT divided by revenue from operations.

- (6) Return on Equity (ROE%) is calculated as a percentage of PAT divided by Average Total Equity at the end of the year /period, whereas Average total equity is calculated as average of opening equity share capital and reserves and surplus and closing equity share capital and reserves and surplus.
- (7) Return on Capital Employed (ROCE%) is calculated as a percentage of EBIT is divided by Average Capital Employed at the end of the year /period, whereas Average capital employed is calculated as average of opening capital employed and closing capital employed. EBIT is calculated as restated profit before tax plus finance costs minus other income. Capital Employed is calculated as Total Equity plus DTA minus DTL, Long Term Borrowings and Short-Term Borrowings.
- (8) Investment in Property, Plant and Equipment is calculated as investment in Computers & Printers, Furniture and Fixtures, Medical Equipment, Office Equipment and Vehicles in a particular period/ year.
- (9) Cash conversion ratio is calculated as cash flow from operations divided by EBITDA.

b) Key operational indicators

Indicator	For the period ended	For the year ended	
	April 01, 2025 to September 30, 2025	2025	2024
Number of diagnostic centres	7	7	8
Number of patients served	51,476	1,03,602	42,129
Number of tests performed	87,307	1,76,248	73,372
Number of tests per patient visit ⁽¹⁾	1.70	1.70	1.74
Individual Consumer Business Revenue (₹ in Lakhs)	1,396.85	2,610.56	1,467.01
Individual Consumer Business as a % of total revenue	82.42%	86.74%	92.67%
Institutional Business Revenue (₹ in Lakhs)	297.88	398.96	116.04
Institutional Business Revenue as a % of total revenue	17.58%	13.26%	6.33%
Average revenue per test (ARPT) (₹) ⁽²⁾	1,941.12/-	1,707.55/-	2,157.57/-
Revenue generated from pathology routine and specialized tests (₹ in Lakhs) ⁽³⁾	168.63	290.25	95.34
Revenue generated from basic radiology tests (₹ in Lakhs) ⁽⁴⁾	302.71	583.56	277.47
Revenue generated from advanced radiology tests (₹ in Lakhs) ⁽⁵⁾	1,223.39	2,135.71	1,210.24

Notes:

- (1) Number of tests per patient visit is derived by dividing the number of tests performed by the number of patients served.
- (2) Average revenue per test is calculated as revenue from operations divided by the number of tests performed.
- (3) Routine tests include: basic biochemistry, basic haematology, clinical pathology and Specialized tests are advanced biochemistry, chemiluminescence immunoassay (CLIA) that combine chemiluminescence technique with immunochemical reactions.
- (4) Basic Radiology tests include ECG, X-rays, and ultrasounds.
- (5) Advance Radiology tests include CT scans and MRI scans and highly specialized nuclear medicine tests such as PET-CT scans, which require advanced machinery to conduct such tests.

As certified by M/s Kanak Rathod and Co, Chartered Accountants, by way of their certificate dated November 18, 2025.

Based on Restated Standalone Financial Information:

a) Key financial indicators

Indicator	For the period ended	For the year ended		
	April 01, 2025 to September 30, 2025	2025	2024	2023
Revenue from Operations (₹ in Lakhs) ⁽¹⁾	1,062.32	1,627.02	968.36	684.29
EBITDA (₹ in Lakhs) ⁽²⁾	457.13	620.56	393.85	170.01
EBITDA Margin (%) ⁽³⁾	43.03%	38.14%	40.67%	24.84%
PAT (₹ in Lakhs) ⁽⁴⁾	366.54	522.74	400.55	23.66
PAT Margin (%) ⁽⁵⁾	34.50%	32.13%	41.36%	3.46%
Return on equity (%) ⁽⁶⁾	20.81%	51.41%	63.62%	4.17%
Return on capital employed (%) ⁽⁷⁾	19.85%	41.66%	37.99%	5.75%
Investment in Property, Plant and Equipment during the year (₹ in Lakhs) ⁽⁸⁾	507.76	21.00	45.37	8.74
Cash Conversion Ratio (times) ⁽⁹⁾	1.27	0.45	0.84	1.00

Notes:

- (1) Revenue from operations is calculated as revenue from sale of services.
- (2) EBITDA is calculated as restated profit before tax, extraordinary and exceptional items plus finance costs, depreciation and amortisation expense minus other income.
- (3) EBITDA margin is calculated as a percentage of EBITDA divided by revenue from operations.
- (4) PAT represents total profit after tax for the year/period.
- (5) PAT margin is calculated as a percentage of PAT divided by revenue from operations.
- (6) Return on Equity (ROE%) is calculated as a percentage of PAT divided by Average Total Equity at the end of the year /period, whereas Average total equity is calculated as average of opening equity share capital and reserves and surplus and closing equity share capital and reserves and surplus.
- (7) Return on Capital Employed (ROCE%) is calculated as a percentage of EBIT is divided by Average Capital Employed at the end of the year /period, whereas Average capital employed is calculated as average of opening capital employed and closing capital employed. EBIT is calculated as restated profit before tax plus finance costs minus other income. Capital Employed is calculated as Total Equity plus DTA minus DTL, Long Term Borrowings and Short-Term Borrowings.
- (8) Investment in Property, Plant and Equipment is calculated as investment in Computers & Printers, Furniture and Fixtures, Medical Equipment, Office Equipment and Vehicles in a particular period/ year.
- (9) Cash conversion ratio is calculated as cash flow from operations divided by EBITDA.

b) Key operational indicators

Indicator	For the period ended	For the year ended		
	April 01, 2025 to September 30, 2025	2025	2024	2023
Number of diagnostic centres	3	3	4	1
Number of patients served	25,606	56,018	24,408	14,498
Number of tests performed	52,069	1,00,676	43,146	20,863
Number of tests per patient visit ⁽¹⁾	2.03	1.80	1.77	1.44
Individual Consumer Business Revenue (₹ in Lakhs)	846.65	1,414.82	877.88	658.59
Individual Consumer Business Revenue as a % of total revenue	79.70%	86.96%	90.66%	96.24%
Institutional Business Revenue (₹ in Lakhs)	215.67	212.20	90.48	25.71
Institutional Business Revenue as a % of total revenue	20.30%	13.04%	9.34%	3.76%
Average revenue per test (ARPT) (₹) ⁽²⁾	2,040.21/-	1,616/-	2,214.2/-	3280/-
Revenue generated from pathology routine and specialized tests (₹ in Lakhs) ⁽³⁾	112.85	193.67	63.30	11.11
Revenue generated from basic radiology tests (₹ in Lakhs) ⁽⁴⁾	131.34	260.02	166.87	112.02
Revenue generated from advanced radiology tests (₹ in Lakhs) ⁽⁵⁾	818.13	1,173.33	738.19	561.16

Notes:

- (1) Number of tests per patient visit is derived by dividing the number of tests performed by the number of patients served.
- (2) Average revenue per test is calculated as revenue from operations divided by the number of tests performed.
- (3) Routine tests include: basic biochemistry, basic haematology, clinical pathology and Specialized tests are advanced biochemistry, chemiluminescence immunoassay (CLIA) that combine chemiluminescence technique with immunochemical reactions.
- (4) Basic Radiology tests include ECG, X-rays, and ultrasounds.

IN THE NATURE OF ABRIDGED PROSPECTUS - MEMORANDUM CONTAINING SALIENT FEATURES OF THE RED HERRING PROSPECTUS

(5) Advance Radiology tests include CT scans and MRI scans and highly specialized nuclear medicine tests such as PET-CT scans, which require advanced machinery to conduct such tests.

As certified by M/s Kanak Rathod and Co, Chartered Accountants, by way of their certificate dated November 18, 2025.

For further details, see “Basis of Issue Price” on page 111 of the RHP.

Industries Served: We serve customers across diagnostic services to identify health conditions, ensuring accurate diagnosis, treatment planning and recovery. Catering to B2B (hospitals, clinics) and B2C (direct customers), these services are segmented into Pathology and Radiology.

Revenue segmentation in terms of top 5/10 clients or Industries: Not Applicable

Intellectual Property, if any: For details of Intellectual Property, see “Our Business – Intellectual Property” on page 188 of the RHP.

Market Share: Not ascertainable.

Manufacturing plant, if any: Not Applicable as we are in service industry.

Employee Strength: As on October 31, 2025, we have 113 full-time employees and 24 regular consultants on retainer basis and 20 Contractual employees, including 5 Key Managerial Personnel & Senior Management Personnel, 4 lab doctors, 18 radiologists and 130 technical staff and phlebotomists.

BOARD OF DIRECTORS

Sr No.	Name	Designation	Experience & Educational Qualification	Other Directorships
1.	Dr. Ketan Jayantilal Jain	Non-Executive Director	Dr. Ketan Jayantilal Jain, Non-Executive Director, holds an M.B.B.S. and a Diploma in Medical Radiology and Electrology and has around 16 years of experience as a consultant radiologist, including founding and managing Asian Imaging for over a decade.	Indian companies: 1. Porteus Medical LLP (Formerly known as “Porteus Path Lab LLP”) 2. Primacare Diagnostic LLP Foreign companies: Nil
2.	Dr. Sanket Vinod Jain	Chairman and Non-Executive Director	Dr. Sanket Vinod Jain, Chairman and Non-Executive Director, holds an M.B.B.S. and an M.D. (Radiodiagnosis) and has around six years of experience as a consultant radiologist with Primacare Healthcare LLP since 2019 and with our Company since 2021.	Indian companies: 1. MSCRIBEIT Infotech LLP (Formerly known as “PCD MedicalLLP”) 2. Porteus Medical LLP (Formerly known as “Porteus Path Lab LLP”) 3. Primacare Diagnostic LLP 4. Primacare Healthcare LLP 5. PCD Diagnostics LLP 6. Invicta Medical LLP Foreign companies: Nil
3.	Aayush Kamleshbhai Shah	Independent Director	Aayush Kamleshbhai Shah, Independent Director, is an Associate Member of ICSI and holds Bachelor of Laws and Bachelor of Commerce degrees. He is Company Secretary of Wealth First Portfolio Managers Limited since 2015 and has 10 years’ experience in corporate and securities laws.	Indian companies: 1. H.M. Electro Mech Limited 2. Katex Exim Limited 3. Siddhi Cotspin Limited 4. Fonebox Retail Limited Foreign companies: Nil
4.	Shilpa Ajay Bhatia	Independent Director	Shilpa Ajay Bhatia, Independent Director, is a Practicing Company Secretary, Associate Member of ICSI, and holds Bachelor of Laws and Bachelor of Commerce degrees. She has around 17 years’ experience in secretarial and corporate laws, restructuring, mergers, amalgamations and fundraising.	Indian companies: 1. Nibe Ordnance and Maritime Limited 2. Coastal Marine Construction and Engineering Limited 3. HREL Real Estate Limited 4. Progrex Ventures Limited Foreign companies: Nil

For the complete profile of our Board of Directors, please refer to the chapter title “Our Management - Brief profile of our directors” beginning on page 211 of the RHP.

OBJECTS OF THE ISSUE

The Issue comprises of a Fresh Issue of up to 33,08,800 Equity Shares aggregating up to ₹ [●] Lakhs, subject to finalization of Basis of Allotment. For details, see “Summary of the Offer Document” and “The Issue” on pages 28 and 70, respectively.

Proposed schedule of implementation and deployment of Net Proceeds:

Sr. No.	Object	Amount to be funded from Net Proceeds (₹ in Lakhs)	Amount to be deployed from the Net Proceeds in Fiscal 2026	Amount to be deployed from the Net Proceeds in Fiscal 2027
1.	Funding capital expenditure for purchase of medical equipment towards establishment of five new diagnostic centres in Maharashtra;	2,111.33	879.35	1,231.98
2.	General Corporate Purposes [#]	[●]	[●]	[●]
	Total	[●]	[●]	[●]

[#] To be finalized upon determination of the Issue Price and updated in the Prospectus prior to filing with ROC. The amount utilized for general corporate purpose shall not exceed 15 % of the Gross Proceeds of the Issue or ₹ 1,000.00 lakhs whichever is lower.

For further details, see “Objects of the Issue” on page 101 of the RHP.

Details and reasons for non-deployment or delay in deployment of proceeds or changes in utilization of issue proceeds of past public issues / rights issue, if any, of the Company in the preceding 10 years: NA

Name of monitoring agency, if any: Not Applicable

Terms of Issuance of Convertible Security, if any: Not Applicable

Shareholding Pattern as on the date of the RHP:

Sr. No.	Particulars	Pre-Issue number of Equity Shares (Number of fully paid-up Equity Shares held)	% Holding of Pre-Issue (Shareholding as a % of total number of shares)
1.	Promoters & Promoter Group	83,84,920	90.52%
2.	Public	8,78,253	9.48%
	Total	92,63,173	100.00%

Number/amount of equity shares proposed to be sold by selling Shareholders, if any: Not Applicable

SUMMARY OF RESTATED FINANCIAL INFORMATION

Based on standalone:

(₹ in Lakhs)

Particulars	For the period ended on	For the year ended 31 st March		
	September 30, 2025	2025	2024	2023
Total income from operations (Net)	1,062.32	1,627.02	968.36	684.29

IN THE NATURE OF ABRIDGED PROSPECTUS - MEMORANDUM CONTAINING SALIENT FEATURES OF THE RED HERRING PROSPECTUS

Net Profit/(Loss) before tax and extraordinary items	485.10	668.39	472.08	31.62
Net Profit / (Loss) after tax and extraordinary items	366.54	522.74	400.55	23.66
Equity Share Capital	926.32	841.79	13.15	503.68
Reserve & Surplus	1,318.55	436.41	742.31	-
Net worth	2,244.87	1,278.20	755.46	503.68
Basic and Diluted earnings per share (₹)	4.12	6.21	4.76	0.28
Return on net worth (%)	16.33%	40.90%	53.02%	4.70%
Net asset value per share (₹)	25.22	15.18	8.97	5.98

Based on consolidated:

(₹ in Lakhs)

Particulars	For the period ended on	For the year ended 31 st March	
	September 30, 2025	2025	2024
Total income from operations (Net)	1,694.73	3,009.52	1,583.05
Net Profit/(Loss) before tax and extraordinary items	542.85	656.36	512.09
Net Profit / (Loss) after tax and extraordinary items	408.41	492.95	380.54
Equity Share Capital	926.32	841.79	13.15
Reserve & Surplus	1,442.06	518.05	853.74
Net worth	2,368.38	1,359.85	866.89
Basic and Diluted earnings per share (₹)	4.59	5.86	4.52
Return on net worth (%)	17.24%	36.25%	43.90%
Net asset value per share (₹)	26.60	16.15	10.30

INTERNAL RISK FACTORS

The below mentioned risks are top 10 risk factors as per the Prospectus:

1. Our business and prospects may be adversely affected if we are unable to maintain and grow our brand name and brand image.
2. Any interruptions at our flagship centre and other diagnostic centres may affect our ability to process diagnostic tests, which in turn may adversely affect our business, results of operations and financial condition.
3. Concentrated emphasis on radiology services also exposes us to substantial risks that could adversely impact our operations, financial performance, and long-term growth prospects.
4. Our operations are concentrated in Mumbai Metropolitan Region ("MMR"), and any loss of business in such region could have an adverse effect on our business, results of operations and financial condition.
5. Our ability to remain competitive may be adversely affected by technological advancements, innovations in diagnostic testing and our ability to access such technology.
6. We operate in a highly competitive business environment, and our inability to compete effectively could have an adverse effect on our business, results of operations and financial condition.
7. Failure to establish and comply with appropriate quality standards when performing imaging, testing and diagnostics services could result in litigation and liability for us and could materially and adversely affect its reputation and results of operations.
8. We may be unable to successfully implement or manage our growth strategy.
9. The Restated Financial Information provided in this Draft Red Herring Prospectus have been provided by the Peer Reviewed Chartered Accountants who are not the Statutory Auditors of our Company.
10. The industry in which we operate possess various risks and challenges as provided in the Industry Report titled "Industry Report on Diagnostic Industry in India" dated July 22, 2024, which is exclusively prepared for the purposes of the Offer and issued by D&B and is commissioned and paid for by our Company ("D&B Report").

For further details, see "Risk Factors" beginning on page 42 of the RHP.

SUMMARY OF OUTSTANDING LITIGATIONS, CLAIMS AND REGULATORY ACTION

A. Total number of outstanding litigations against our Company and amount involved:

Name of Entity	Criminal Proceedings	Tax Proceedings	Statutory or Regulatory Proceedings	Disciplinary actions by the SEBI or Stock Exchanges against our Promoters	Material Civil Litigations	Aggregate amount Involved (Rs in Lakhs)
Company						
By the Company	Nil	Nil	Nil	Nil	Nil	Nil
Against the Company	Nil	2	Nil	Nil	Nil	0.002
Promoters						
By Promoters	Nil	Nil	Nil	Nil	Nil	Nil
Against Promoters	Nil	8	Nil	Nil	Nil	0.602
Directors (Other than Promoters)						
By Directors	Nil	Nil	Nil	Nil	Nil	Nil
Against the Directors	Nil	Nil	Nil	Nil	Nil	Nil
Subsidiaries						
By Subsidiaries	Nil	Nil	Nil	Nil	Nil	Nil
Against Subsidiaries	Nil	8	Nil	Nil	Nil	0.98
Key Managerial Personnel & Senior Management Personnel						
By KMPs/ SMPs	Nil	Nil	Nil	Nil	Nil	Nil
Against KMPs/ SMPs	Nil	Nil	Nil	Nil	Nil	Nil

Determined in accordance with the Materiality Policy.

B. Brief details of top 5 material outstanding litigations against the company and amount involved: Not Applicable

C. Regulatory Action, if any - disciplinary action taken by SEBI or stock exchanges against the Promoters in last 5 financial years including outstanding action, if any: Not Applicable

D. Details of outstanding criminal proceedings against Promoters: Not Applicable

ANY OTHER IMPORTANT INFORMATION AS PER BRML / ISSUER COMPANY - NIL

DECLARATION BY THE COMPANY

We hereby certify and declare that all relevant provisions of the Companies Act, 2013 and the rules, regulations and guidelines issued by the Government, or the rules, regulations or guidelines issued by SEBI, established under Section 3 of the SEBI Act, as the case may be, have been complied with, and no statement made in the Red Herring Prospectus is contrary to the provisions of the Companies Act, 2013, the SCRA, the SCRR and the SEBI Act, each as amended, or the rules made, or regulations or guidelines issued thereunder, as the case may be. We further certify that all the statements made in the Red Herring Prospectus are true and correct.

LIST OF SELF CERTIFIED SYNDICATE BANKS (SCSBs) UNDER THE ASBA PROCESS

Sr. No.	Name of the Bank	Controlling Branch & Address	Contact Person	Telephone Number	Fax Number	Email
1.	Axis Bank Ltd.	Centralised Collections and Payment Hub (CCPH) 5th Floor, Gigaplex, Building No. 1, Plot No. I.T.5, MIDC, Airoli Knowledge Park, Airoli, Navi Mumbai - 400708	Mr. Sunil Fadtare Assitant Vice President	022-71315906, 9819803730	022- 71315994	Sunil.fadtare@axisbank.com
2.	AU Small Finance Bank Limited	CP3 235, Industrial Area, Apparel Park, Mahal Road, Jagatpura, Jaipur, Rajasthan 302022	Vikrant Singh Sirohi	Mobile : +91 7340012357	-	cpcasba@aubank.in
3.	Bandhan Bank	Adventz Infinity@5, BN Block, Sector V, Salt Lake City, Kolkata	Sagar Ranjan Das Senior Manager	Mobile : 9022339164	-	asba.business@bandhanbank.com
4.	Bank of Baroda	Mumbai Main Office, 10/12 Mumbai Samachar Marg, Fort, Mumbai-23	Mr. Sonu A. Arekar	022-40468314, 40468307,	022-22835236	asba.fortap@bankofbaroda.com
5.	Bank of Maharashtra	Fort Branch, 1st Floor, Jammangal, 45/47, Mumbai Samachar Marg, Mumbai - 400023	SHRI. V R Kshirsagar (DGM)	022-22694160 22652595 22663947	022-22681296	brmgr2@mahabank.co.in; bom2@mahabank.co.in
6.	BNP Paribas	BNP Paribas House, 1, North Avenue, Maker Maxity, Bandra Kurla Complex, Bandra (East), Mumbai - 400051	Mr. Ashish. Chaturvedi, Mr. Dipu SA, Ms Prathima Madiwala	(022) 61964570/61964594/61964592	(022) 61964595	Ashish.chaturvedi@asia. bnpparibas.comdipu.sa@asia. bnpparibas.comprathima. madiwala@asia.bnpparibas.com
7.	Barclays Bank PLC	Barclays Bank PLC 601/603 Ceejay House, Shivsagar Estate, Dr Annie Besant Road, Worli, Mumbai - 400018	Parul Parmar	+91- 22 6719 6400/ 6575	+91- 22 6719 6996	Parul.parmar@barclays.com
8.	Bank of India	Phiroze Jeejeebhoy Tower, (New Stock Exchange Bldg), P. J. Tower, Dalal Street, Fort, Mumbai - 400 023.	Shri Navin Kumar Pathak, Senior Manager	022-22723631/1677/ 9619810717	022-22721782	Stockexchange.Mumbai, south@bankofindia.co.in
9.	Credit Suisse	10th Floor, Ceejay House, Plot F, Shivsagar Estate, Dr. Annie Besant Road, Worli, Mumbai - 400018.	Yogesh Bachwani	098216 13306	-	yogesh.bachwani@credit-suisse.com
10.	CITI Bank NA	Citigroup Center, Plot No C-61, Bandra-Kurla Complex, Bandra (E), Mumbai - 400 051	S Girish	022-26535504, 98199 12248	022-26535824	s.girish@citi.com, asba.ops@ citi.com
11.	Central Bank of India	Ground floor, Central Bank of India, Central Bank Building, Fort, Mumbai 400001	Mr. Vineet Bansaj	022- 22623148, 22623149	022-22623150	asba4082@centralbank.co.in
12.	Canara Bank	Canara Bank, Capital Market Service Branch,407, 4th floor, Himalaya House79, Mata Ramabai Ambedkar, Marg, MUMBAI-400 001	Mr. Arvind Namdev Pawar	022-22661618/ 22692973/ 9769303555	022-22664140	cb2422@canarabank.com, mbdcomcity@canarabank.com, hocmbd@canarabank.com
13.	City Union Bank Ltd.	48, Mahalakshmi St., T. Nagar, Chennai - 600 017.Tamil Nadu.	Sivaraman	044 - 24340010, 24343517, 24346060, 24348586, 9380286558, 9382642081	044 - 24348586	cub001@cityunionbank.com
14.	DBS Bank Ltd.	DBS Bank Ltd, Fort House, 221, Dr. D.N. Road, Fort, Mumbai, 400 001	Amol Natekar	+91 22 6613 1213	+91 22 6752 8470	amolnatekar@db.com
15.	DCB Bank	154, S.V.Patel Road, Dongri (E), Pin - 400009.	Meenaz Hasanali Thanawala	022-67474170	-	meenaz@dcbbank.com
16.	Dhanlaxmi Bank Limited	Ground Floor, Jammabhooni Bhavan, Plot 11 -12, Jammabhooni Marg, Fort Mumbai, Maharashtra - 400 001	Ramesh Menon	9167832288, 022- 22871658	-	ramesh.menon@dhanbank.co.in
17.	Deutsche Bank	Sidrah, 110, Swami Vivekananda Road, Khar (West), Mumbai 400052	Ms. Hetal Dholakia	(91) (022) 6600 9428 (91) (022) 6600 9419	-	hetal.dholakia@db.com manoj-s.naik@db.com; nanette. daryanani@db.com.
18.	Equitas Small Finance Bank	CPC, Phase II, 4th floor, Spencer Plaza, No 769, Anna Salai, Chennai - 600002	Chandrashekar Arumugam	(M) 8939886802	-	asbaoperations@equitasbank.com; asbarecon@equitasbank.com
19.	GP Parsik Sahakari Bank Limited	Shivram Patil Bhavan, Parsik Nagar, Kalwa, Thane	Mr.Mayur M.Tanksale	022-25456655	-	mmmtanksale800@gpparsikbank.net / pjsbasba@gpparsikbank.net
20.	HSBC Ltd.	3rd Floor, PCM Dept. Umang, Plot CTS No. 1406-A/28, Mindspace, Malad (West) Mumbai 400 064 (address of IPO Operations office)	Mr Jagrut Joshi	(022) 67115485/ 9870403732	(022) 66536005	jagrutjoshi@hsbc.co.in
21.	HDFC Bank Ltd.	FIG - OPS Department HDFC Bank Ltd Lodha - I Think Techno Campus O-3 Level Next to Kanjurmarg Railway Station Kanjurmarg (East) Mumbai - 400042	Vincent Dsouza / Siddharth Jadhav / Prasanna Uchil	022-30752929 / 2927 / 2928	-	vincent.dsouza@hdfcbank.com, siddharth.jadhav@hdfcbank.com, prasanna. uchil@hdfcbank.com
22.	IDFC First Bank	Building no 2, Mindspace TTC Industrial Area, Juinagar. Navi Mumbai - 400 706	Mr. V M Praveen	022-49850025/ 9819708055	-	ASBA.CB@idfcfirstbank.com
23.	ICICI Bank Ltd.	ICICI BANK LIMITED, Capital Market Division, 1st Floor, 122, Mistry Bhavan, Dinshaw Vachha Road, Backbay Reclamation, Churchgate, Mumbai	Roshan Tellis	022-22859874/803	022-22611138	roshan.tellis@icicibank.com
24.	IDBI Bank Ltd.	IDBI Bank Limited Central Processing Unit, Sarju House, 3rd Floor, Plot No 7, Street No. 15, Andheri MIDC, Andheri (E), Mumbai.Pin : 400093	Shri. Naveen Nischal HP / Shri Viral Barodia	022- 66700525 / 685	-	hp.naveennischal@idbi.co.in / barodia.viral@idbi.co.in
25.	Indian Bank	Nandanam Branch- 480 Anna Salai, Nandanam 600035	Mr. V Muthukumar, Mr. M Veerabahu	044 24330233	044 24347755	nandanam@indianbank.co.in
26.	IndusInd Bank	IndusInd Bank Ltd. Fort Branch Sonawalla Bldg, Mumbai Samachar Marg, Fort, Mumbai 400001	Yogesh Adke Dy. Vice President	022-66366589 / 91 / 929833670809	022-22644834	yogesh.adke@indusind.com
27.	Indian Overseas Bank	Mexxanine Floor, Cathedral Branch, 762 Anna Salai, Chennai 600 002	Mr. V. Srinivasan	044 - 28513616	-	deposit@jobnet.co.in
28.	J P Morgan Chase Bank, N.A.	J.P. Morgan Tower, Off C.S.T. Road, Kalina Santacruz - East, Mumbai - 400 098	Mahesh Aras	022-61573811	022-61573949	Mahesh.aras@jpmorgan. comIndia.operations@jpmorgan.com
29.	Janata Sahakari Bank Ltd.	N S D L Department Bharat Bhavan, 1360, Shukrawar Peth, Pune -411002	Shri. Ajit Manohar Sane+91 9960239391	+91 (20) 24431011 +91 (20) 24431016 +91 9503058993	+91 (20) 24431014	jsbnsdl@dataone.in
30.	Karur Vysya Bank Ltd.	Demat Cell, Second Floor No 29, Rangan Street, T Nagar, Chennai - 600 017	Maruthi Kumar Yenamandra	044- 24340374	044-24340374	maruthikumar@kvbmail.com, kvbdp@kvbmail.com

Sr. No.	Name of the Bank	Controlling Branch & Address	Contact Person	Telephone Number	Fax Number	Email
31.	Karnataka Bank Ltd	The Karnataka Bank Ltd Mangalore-H O Complex Branch Mahaveera Circle Kankanady Mangalore - 575002	Ravindranath Baglodi [Sr.Manager]	Ph: 0824-2228139 /140 /141	Fax: 0824-2228138	Email: mlr.hocomplex@ktkbank.com
32.	Kotak Mahindra Bank Ltd.	Kotak Infinity, 6 th Floor, Building No. 21, Infinity Park, Off Western Express Highway, General AK Vaidya Marg, Malad(E)	Prashant Sawant	D-+91 22 6605 6959M-+91 9967636316	+91 66056642	prashant.sawant@kotak.com
33.	Mehsana Urban Co-Op. Bank Ltd.	Head Office, Urban Bank Road, Highway, Mehsana - 384002	Branch Manager	+91-2762-251908	+91-2762-240762	asba@mucbank.com
34.	Nutan Nagrik Sahakari Bank Ltd.	Opp Samratshwar Mahadev, Nr, Law Garden, Ellisbridge, Ahmedabad-380006	Miti Shah	9879506795	7926564715	smiti@1977@yahoo.com
35.	Punjab National Bank	Capital Market Services Branch, PNB House, Fort, Sir P.M.Road Mumbai	Sh. K Kumar Raja	Tel - 022- 22621122, 22621123,	022 - 22621124	pnbcapsmbai@pnb.co.in
36.	Punjab & Sind Bank	Rajindera Place- 21 Rajindra Place Bank House New Delhi-110008	RPS Sandhu	011- 25825784/25711836 9911129088	-	d0606@psb.co.in
37.	RBL Bank Limited	Techniplex - I, 9 th Floor, Off Veer Savarkar Flyover, Goregaon (West), Mumbai - 400062.	Shashikanth Sanil	022-40288193, 022-40288196, 022-40288197	022-40288195	asba_ops@rblbank.com
38.	Rajkot Nagarik Sahakari Bank Ltd.	Nagrik Bhavan No 1 Parabazar Dhebarbhai Road Rajkot	Shri Yogesh Raveshiya	9427495222	(0281) 2233916/17/18	khumesh@rmbindia.com; asba@rmbindia.com
39.	State Bank of Hyderabad	Gunfoundry, Hyderabad	Sri Ashok Kulkarni	040-23387325	040-23387743	gunfoundry@sbyhd.co.in
40.	State Bank of Travencore	Anakachery Buildings, Y M C A Road, Statue, Thiruvananthapuram-695001	P. P. Muralidharan	0471-2333676	0471-2338134	dptvm@sbt.co.in
41.	SVC Co-Operative Bank Ltd.	Unit No.601-602-603 Dosti Pinnacle Plot No. E-7, Road No.22, Wagle Estate, Thane 400604	Mr. Omkar Anil Sukhathankar	(O) 71991460 71991461 71991462 71991463 71991465	-	sukhathankaroa@svcbank.com
42.	State Bank of Bikaner & Jaipur	Financial Super Market Branch, Apex Mall, Tonk Road, Jaipur	Shri N K Chandak	0141-27444159413398505	0141-2744457	sbbj11060@sbbj.co.in innkchandak@sbbj.co.in
43.	State Bank of India	State Bank of India, Capital Market Branch(11777),Videocon Heritage Building(Killick House),Charanjit Rai Marg, Fort, Mumbai - 400 001.	Ms. Raviti	Telephone:022-22094932 Mobile:9870498689	022-22094921	nib.11777@sbi.co.in
44.	Standard Chartered Bank	Crescenzo, 3rd Floor, C/38-39, G-Block, Opposite MCA Club, Bandra-Kurla Complex, Bandra [East], Mumbai 400-051	Rohan Ganpule	022 - 61157250 / 022 - 61157234	022 -26757358	lpo.scb@sc.com
45.	Syndicate Bank	Capital Market Service Branch, 26A, First Floor, Syndicate Building, P.M. Road, Fort, Mumbai.	P Padmavathy Sundaram, Chief Manager	022-22621844	022-22700997	padmas@syndicatebank.co.in/ cmssc@syndicatebank.co.in
46.	South Indian Bank	ASBA Cell (NODAL OFFICE) 2nd Floor, Shanu Towers, North Kalamassery, Ernakulam, Kerala - 683 104	John K Mechery	9645817905	0484-2351923	asba@sib.co.in
47.	State Bank of Patiala	CO 99-102, Sector - 8C, Chandigarh	Shri. Amarjit Singh Gim	0172-2779116, 2546124, 254386809779586096	0172-2546080	b5597@sbp.co.in
48.	State Bank of Mysore	P. B. No. 1066. # 24/28, Cama Building, Dalal Street, Fort, Mumbai -400 001	Shailendra kumar	7208048007022- 22678041	022-22656346	s.kumar@sbm.co.indialst@sbm.co.in
49.	The Federal Bank Limited	ASBA CELL, Retail Business Dept., Federal Bank, Marine Drive, Ernakulam 682031	Dhanya Dominic	0484-2201847	4842385605	rbd@federalbank.co.indhanyad@federalbank.co.inriyacob@federalbank.co.in
50.	Tamilnad Mercantile Bank Ltd.	Tamilnad Mercantile Bank Ltd., Depository Participant Services Cell Third Floor, Plot No.4923, A/16, 2nd Avenue, Anna Nagar (West), Chennai - 600 040, Tamilnadu, India	Mr. N. Rajasegaran	044-26192552	044-26204174	dps@tmbonline.com
51.	The Jammu & Kashmir Bank Ltd.	79 A, Mehta House, Bombay Samachar Marg, Fort, Mumbai - 400 023.	Ashfaq Ahmad	9987984105, 022-66595971	022-6634183	bombay@jkbmail.com
52.	The Kalupur Commercial Co-Operative Bank Ltd.	Kalupur Bank Bhavan, Nr. Income Tax Circle, Ashram Road, Ahmedabad-380 014	Jay V. Pathak Manager	079-27582028	079-27544666	jay@kalupurbank.com
53.	The Lakshmi Vilas Bank Ltd.	Bharat House, Ground Floor, 104, Bombay Samachar Marg, Fort Mumbai - 400 001.	S Ramanan	022-22672255-22672247(M)- 22673435(CM)	022-22670267	Mumbaiort_bm@lvbank.in
54.	The Surat Peoples Co-op Bank Ltd	Central Office. Vasudhara Bhavan, Timaliyawad, Nanpura, Surat - 395001	Mr. Iqbal Shaikh	0261-2464577	0261-2464577,592	Iqbal.shaikh@spcbl.in
55.	The Saraswat Co-operative Bank Ltd.	Madhushree, Plot No. 85, District Business Centre, Sector - 17, Vashi, Navi Mumbai - 400703	Mr. Ajit Babaji Satam	022-27884161 27884162 27884163 27884164	022-27884153	ab_satam@saraswatbank.com
56.	TJSB Sahakari Bank Ltd	2nd Floor, Madhukar Bhavan, Road No.16, Wagle Estate	Department Head	022-25838525/530/520		tjsbasba@tjsb.co.in
57.	Union Bank of India	MUMBAI SAMACHAR MARG,66/80, Mumbai Samachar Marg, Post Bag No.253 & 518, Fort, Mumbai - 400023.	Mr. D B JAISWAR	022-22629408	022- 22676685	jaiswar@unionbankofindia.com
58.	UCO Bank	Mumbai Main (Retail) Br., UCO Bank Bldg., D. N. Road, Mumbai- 400 023	Manager	022 40180117 9022457840	022-2222870754	bo.dnroad@mtnl.net.in
59.	Yes Bank Ltd.	YES Bank Limited, Indiabulls Finance Centre, Tower -II , 8th Floor, Senapati Bapat Marg, Elphinstone Road, Mumbai - 400 013.	Alok Srivastava / Shankar Vichare / Avinash Pawar	022 3347 7374/ 7259/ 7251	022 24214504	dlbtiservices@yesbank.in
60.	The Ahmedabad Mercantile Co-Op. Bank Ltd.	Head office :- "Amco House", Nr. Stadium Circle, Navrangpura, Ahmedabad-09	Bimal P Chokshi	079-26426582-84-88	079-26564863	amcoasba@rediffmail.com
61.	Catholic Syrian Bank Ltd.	P B No. 1900, Ground Floor, Marshall Annex Building, Soorji Vallabhdas Marg, Ballard Estate, Mumbai, Maharashtra, Pin-400001	Ram Mohan G S	022-64502165, 022-22664269, 022-22665865, 022-22650850	-	mumbaiort@csb.co.in

ASBA Applicants may approach any of the above banks for submitting their application in the issue. For the complete list of SCSBs and their Designated Branches please refer to the website of SEBI <https://www.sebi.gov.in/sebiweb/other/OtherAction.do?doRecognisedFpi=yes&intmId=34>. A list of SCSBs is also displayed on the website of NSE at www.nseindia.com.